Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12832578 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL3915502 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL189532 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL7269130 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL5449679 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL1527314 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL1527315 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL20573107 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL20573120 | 1.00 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHSD11B1 | |
| SCHEMBL11611772 | 0.89 | SLC6A12 (0.48) | MEN1NPC1RAB9AKMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008866-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-01-10 | — | — | US | disclosed |
| EP-3089970-B1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10085985-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20160331749-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-11-17 | — | — | US | disclosed |
| EP-3089970-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9428514-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-08-30 | — | — | US | disclosed |
| WO-2015089075-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150158873-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-11 | — | — | US | disclosed |
| EP-1797065-A4 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-1797065-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085985-B2 | Bromodomain inhibitors | BRD4, BRD3, BRD1 | MEN1 596/4885NPC1 2523/4885RAB9A 3453/4885 |
| US-20190008866-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MEN1 596/4885NPC1 2523/4885RAB9A 3453/4885 |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | MEN1 1683/4885NPC1 688/4885RAB9A 3846/4885 |
| US-20160331749-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MEN1 596/4885NPC1 2523/4885RAB9A 3453/4885 |
| US-20150158873-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MEN1 596/4885NPC1 2523/4885RAB9A 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.